Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726658 · ClinicalTrials.gov registry record · Phase 1
Zelquistinel in the Treatment of Adults With Major Depressive Disorder
A Phase 1 study, sponsored by Syndeio Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 226
- Enrollment target
NCT03726658 is a Phase 1 study that has completed, run by Syndeio Biosciences. The registered enrollment target is 226 participants.
The verdict
NCT03726658, a Phase 1 study, has completed, sponsored by Syndeio Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 226 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
Interventions
- DRUG Placebo
- DRUG AGN-241751
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2018-11-08 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03726658
The ClinicalTrials.gov registry entry for NCT03726658 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndeio Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03726658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03726658 about?
NCT03726658 is a clinical study titled "Zelquistinel in the Treatment of Adults With Major Depressive Disorder". The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
What is the current status of trial NCT03726658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 226 participants. The study started on 2018-11-08. Estimated completion is 2019-10-23.
What interventions are being tested in trial NCT03726658?
The interventions under investigation include: Placebo (DRUG), AGN-241751 (DRUG).
Who is sponsoring clinical trial NCT03726658?
This trial is sponsored by Syndeio Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.